Statins for improving renal outcomes: A meta-analysis

被引:373
作者
Sandhu, Sabrina
Wiebe, Natasha
Fried, Linda F.
Tonelli, Marcello
机构
[1] Univ Alberta, Div Nephrol & Immunol, Edmonton, AB T6B 2B7, Canada
[2] Univ Alberta, Dept Med, Edmonton, AB T6B 2B7, Canada
[3] Univ Alberta, Dept Crit Care, Edmonton, AB T6B 2B7, Canada
[4] Univ Alberta, Dept Publ Hlth Sci, Edmonton, AB T6B 2B7, Canada
[5] Inst Hlth Econ, Edmonton, AB, Canada
[6] Univ Pittsburgh, Sch Med, Vet Affairs Pittsburgh Healthcare Syst & Renal El, Pittsburgh, PA USA
来源
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2006年 / 17卷 / 07期
关键词
D O I
10.1681/ASN.2006010012
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Statirts frequently are used to prevent cardiovascular events. Several recent studies suggest that statins also may have renal benefits, although this is controversial. This systematic review and meta-analysis were performed to assess the effect of statins on change in kidney function and urinary protein excretion. Medline, EMBASE, the Cochrane Central Register of Controlled Trials, conference proceedings, and the authors' personal files were searched. Published or unpublished randomized, controlled trials or crossover trials of statins that reported assessment of kidney function or proteirturia were included, and studies of individuals with ESRD were excluded. Data were extracted for study design, subject characteristics, type of statin and dose, baseline/change in cholesterol levels, and outcomes (change in measured or estimated GFR [eGFR] and/or urinary protein excretion). Weighted mean differences were calculated for the change in GFR between statin and control groups using a random-effects model. A random-effects model also was used to calculate the standardized mean difference for the change in urinary protein excretion between groups. Twenty-seven eligible studies with 39,704 participants (21 with data for eGFR and 20 for proteinuria or albuminuria) were identified. Overall, the change in the weighted mean differences for eGFR was statistically significant (1.22 nd/min per yr slower in statin recipients; 95% confidence interval [CI] 0.44 to 2.00). In subgroup analysis, the benefit of statin therapy was statistically significant in studies of participants with cardiovascular disease (0.93 ml/min per yr slower than control subjects; 95% CI 0.10 to 1.76) but was NS for studies of participants with diabetic or hypertensive kidney disease or glomerulonephritis. The standardized mean difference for the reduction in albuminuria or proteinuria as a result of statin therapy was statistically significant (0.58 units of SD greater in statin recipients; 95% CI 0.17 to 0.98). Statin therapy seems to reduce proteinuria modestly and results in a small reduction in the rate of kidney function loss, especially in populations with cardiovascular disease.
引用
收藏
页码:2006 / 2016
页数:11
相关论文
共 69 条
[1]  
Aranda Arcas J L, 1994, An Med Interna, V11, P523
[2]   Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria [J].
Asselbergs, FW ;
Diercks, GFH ;
Hillege, HL ;
van Boven, AJ ;
Janssen, WMT ;
Voors, AA ;
de Zeeuw, D ;
de Jong, PE ;
van Veldhuisen, DJ ;
van Gilst, WH .
CIRCULATION, 2004, 110 (18) :2809-2816
[3]   The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study [J].
Athyros, VG ;
Mikhailidis, DP ;
Papageorgiou, AA ;
Symeonidis, AN ;
Pehlivanidis, AN ;
Bouloukos, VI ;
Elisaf, M .
JOURNAL OF CLINICAL PATHOLOGY, 2004, 57 (07) :728-734
[4]   Apolipoprotein B-containing lipoproteins in renal failure: The relation to mode of dialysis [J].
Attman, POA ;
Samuelsson, OG ;
Moberly, J ;
Johansson, AC ;
Ljungman, S ;
Weiss, LG ;
Knight-Gibson, C ;
Alaupovic, P .
KIDNEY INTERNATIONAL, 1999, 55 (04) :1536-1542
[5]   Study of Heart and Renal Protection (SHARP) [J].
Baigent, C ;
Landry, M .
KIDNEY INTERNATIONAL, 2003, 63 :S207-S210
[6]  
Bergesio F, 1996, J NEPHROL, V9, P35
[7]   A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease [J].
Bianchi, S ;
Bigazzi, R ;
Caiazza, A ;
Campese, VM .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2003, 41 (03) :565-570
[8]  
Bracken Michael B., 1992, P13
[9]   Effect of fluvastatin on proteinuria in patients with immunoglobulin A nephropathy [J].
Buemi, M ;
Allegra, A ;
Corica, F ;
Aloisi, C ;
Giacobbe, M ;
Pettinato, G ;
Corsonello, A ;
Senatore, M ;
Frisina, N .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2000, 67 (04) :427-431
[10]  
*COCH COLL, 2004, REV MAN